Paraneoplastik Romatolojik Sendromlar
Özet
Paraneoplastik romatolojik sendromlar, vücuttaki çeşitli malign hastalıklarla ilişkili olarak ortaya çıkan, ancak tümörün doğrudan lokal invazyonundan ya da metastatik yayılımından tamamen bağımsız gelişen nadir kas-iskelet sistemi bozukluklarıdır. Kanser hastalarının yaklaşık yüzde ellisi gibi önemli bir oranı, hastalık süreçleri esnasında en az bir kez paraneoplastik semptom deneyimi yaşamaktadır. Bu sendromların karmaşık patogenezinde; virüsler veya radyasyon gibi ortak bağımsız nedenlerin tetiklemesi, tümör hücrelerince üretilen ve inflamasyonu başlatan toksinler ya da apopitotik kanser hücrelerinden salınan antijenlere karşı gelişen hipersensitivite reaksiyonları olmak üzere üç temel mekanizma ileri sürülmektedir. Klinik yelpazesi son derece geniş olup paraneoplastik poliartrit, hipertrofik osteoartropati, amiloid artriti, RS3PE sendromu, vaskülitler, Raynaud sendromu, kanserle ilişkili miyozitler ve eozinofilik fasiit gibi pek çok farklı tabloyu barındırır. Özellikle elli yaş ve üzerindeki erkek hastalarda hızlı başlangıçlı, standart steroid tedavilerine dirençli, asimetrik alt ekstremite tutulumu gösteren ve belirgin yapısal semptomların eşlik ettiği atipik poliartrit vakalarında gizli tümör varlığı mutlaka akla getirilmelidir. Açıklanamayan anemi, romatoid nodül yokluğu ve yüksek laktat dehidrogenez seviyeleri tanısal şüpheyi artırır. En net nedensellik kanıtı, altta yatan malignitenin cerrahi veya kemoradyoterapi ile tamamen ortadan kaldırılmasıyla romatizmal semptomların tam iyileşme göstermesidir. Bu nedenle klinisyenlerin bu sendromları tanıması, gizli tümörlerin erken tespiti için hayati önem taşır.
Paraneoplastic rheumatological syndromes are rare musculoskeletal disorders associated with various malignant diseases, developing completely independently of the direct local invasion or metastatic spread of the tumor. A significant proportion of cancer patients, approximately fifty percent, experience paraneoplastic symptoms at least once during the course of their illness. Three main mechanisms are proposed in their complex pathogenesis: triggering by shared independent causes like viruses or radiation, inflammation initiated by toxins produced by tumor cells, or hypersensitivity reactions against intracellular antigens released by apoptotic cancer cells. The clinical spectrum is extremely broad, encompassing numerous distinct conditions such as paraneoplastic polyarthritis, hypertrophic osteoarthropathy, amyloid arthritis, RS3PE syndrome, paraneoplastic vasculitis, Raynaud's syndrome, cancer-associated myositis, and eosinophilic fasciitis. Particularly in male patients aged fifty and older, an occult malignancy must be considered in cases of atypical polyarthritis characterized by rapid onset, resistance to standard steroid treatments, asymmetric lower extremity involvement, and prominent constitutional symptoms. Unexplained anemia, the absence of rheumatoid nodules, and elevated lactate dehydrogenase levels increase diagnostic suspicion. The most definitive evidence of causality is the complete resolution of rheumatic symptoms once the underlying malignancy is entirely eradicated through surgery or chemoradiotherapy. Therefore, recognition of these syndromes by clinicians is vital for the early detection and treatment of hidden tumors.
Referanslar
Trieu J, Sinnathamby M, Di Bella C, et al. Choong, Biopsy and the diagnostic evaluation of musculoskeletal tumours: critical but often missed in the 21st century. ANZ J. Surg. 2016;86(3) 133–138.
Brix N, Rosthøj S, Herlin S, et al. Arthritis as presenting manifestation of acute lymphoblastic leukaemia in children. Arch. Dis. Child. 2015;100(9) 821–825.
Singer O, Cigler T, Moore A.B, et al. Defining the aromatase inhibitor musculoskeletal syndrome: a prospective study. Arthritis Care Res. 2012;64(12) 1910–1918.
Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol. Int. 2006;26(6) 481–488.
Suarez-Almazor M.E, Kim S.T, Abdel-Wahab N, et al. Review: immune-related adverse events with use of checkpoint inhibitors for immunotherapy of cancer. Arthritis Rheum. 2017;69(4) 687–699.
Manger B, Schett G, Paraneoplastic syndromes in rheumatology. Nat. Rev. Rheumatol. 2014:10(11) 662–670.
Azar L, Khasnis A. Paraneoplastic rheumatologic syndromes. Curr. Opin. Rheumatol. 2013:25(1) 44–49.
Nathanson L, TC Hall. Introduction: paraneoplastic syndromes. Semin Oncol 1997;24(3):265-8.
Naschitz J.E, Rosner I: Musculoskeletal syndromes associated with malignancy (excluding hypertrophic osteoarthropathy). Curr Opin Rheumatol. 2008;20(1). 100-105.
De Figueiredo IR, Alves RV, Castro SG, et al. Rheumatologic disease as paraneoplastic syndromes – a paradigmatic case. J Rheum Dis Treat. 2018;4:067.
Kisacik B, Onat AM, Kasifoglu T, et al. Diagnostic dilemma of paraneoplastic arthritis: case series. Int J Rheum Dis. 2014:17(6):640–645.
Morel J, et al. Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann.Rheum. Dis. 2008:67, 244-247.
Yamashita, H et al. Characteristics of 10 patients with rheumatologic musculoskeletal manifestations. Mod. Rheumatol. 2014: 24, 492-498.
Ito T, Goto K, Yoh K, et al. Hypertrophic pulmonary osteoarthropathy as paraneoplastic manifestation of lung cancer. J Thorac Oncol. 2010;5:976–980.
Atkinson S, Fox SB: Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol. 2004;203(2):721–728.
Shih W.J. Pulmonary hypertrophic osteoartropathy and its resolution. Semin. Nucl. Med. 2004;34,159-163.
Jhonson S.A, Spiller P.A, CM Faull. Treatment of resistant pain in hyperthrophic pulmonary osteoartropathy with subcutaneous ocreotide. Thorax 52, 298-299 (1997).
Fam AG. Paraneoplastic rheumatic syndromes. Baillierres Best PractRes Clin Rheumatol. 2000;14:515-33.
Katz GA, Peter JB, Person CM, et al. The shoulder-pad sign-a diagnostic feature of amyloid arthropathy. N Eng J Med.1973;288:354-5.
Bhakta BB, Pease CT. Late-onset rheumatoid arthritis: is pitting oedema of the hands at onset a good prognostic indicator? Br J Rheumatol. 1997;36:214–9.
Hongbin L, Altman RD, Yao Q: RS3PE: clinical and research development.Curr Rheumatol Rep. 2015 17(8):49.
Russell EB. Remitting seronegative symmetrical synovitis with pitting edema syndrome: followup for neoplasia. J Rheumatol. 2005;32:1760–1.
Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis. 2005;64:1653–5.
Oide T, Ohara S, Oguchi K, et al. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome in Nagano,Japan: clinical, radiological, and cytokine studies of 13 patients. Clin Exp Rheumatol. 2004;22:91–8.
Origuchi T, Arima K, Kawashiri SY, et al. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edemasyndrome. Mod Rheumatol. 2012;22:584–8.
Manger B, Schett G. Palmar fasciitis and polyarthritis syndrome- systematic literatüre review of 100 cases. Semin Arthritis Rheum. 2014;44:105-11.
Sendur OF. Paraneoplastic rheumatic disorders. Turk Journal of rheumatology. 2012;27:18-23.
Ihn H. Pathogenesis of fibrosis: role of TGF-beta and CTGF. Curr Opin Rheumatol. 2002; 14: 681-5.
Sung YK, Park MY, Yoo DH. Idiopathic Palmar Fasciitis with Polyarthritis Syndrome. Korean Med Sci. 2006; 21:1128-32.
Narváez J, Bianchi MM, Santo P, et al. Pancreatitis, panniculitis, and polyarthritis. Semin Arthritis Rheum.2010;39(5):417–423.
Betrains A, Rosseels W, Van Mieghem E,et al. Clinical characteristics, treatment, and outcome of pancreatitis, panniculitis, and polyarthritis syndrome: a case-based review.Clin Rheumatol. 2021;40(4):1625-1633.
Zundler S, Erber R, Agaimy A, et al. Pancreatic panniculitis in a patient with pancreatic-type acinar cell carcinoma of the liver—case report and review of literatüre. BMC Canc. 2016:130.
Kalgaard OM, Seem E, Kvernebo K: Erythromelalgia: a clinical study of 87 cases. J Intern Med .1997;242:191.
Mork C, Asker CL, Salerud EG, et al. Microvascular arteriovenous shunting is a probable pathogenic mechanism in erythromelalgia. J Invest Dermatol 43:841, 2000.
Davis MD, Weenig RH, Genebriera J, et al. Histopathologic findings in primary erythromelalgia are nonspecific: special studies show a decrease in small nerve fiber density. J Am Acad Dermatol 2006; 55:519.
Cohen JS: Erythromelalgia: new theories and new therapies, J AmAcad Dermatol2000:43(5 Pt 1):841.
Manger B, Schett G. Rheumatic paraneoplastic syndromes-a clinical link between malignancy and autoimmunity. Clin immunol. 2018;186:67-70.
RacenelliV, Prete M, Minoia C, et al. Rheumatic disorders as paraneoplastic syndromes. Autoimmun Rev. 2008;7:352-8.
Greer JM, Longley S, Edwards NL et al. Vasculitis associated with malignancy. Experience with 13 patients and literature review. Medicine (Baltimore). 1988;67:220-30.
Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum. 2007;57: 1473-80.
Andras C, Csiki Z, Ponyi A, et al. Paraneoplastic reumatic syndromes. Rheumatol Int.2006;26:374-6-82.
Ciolkiewcz M, Domysóawaska I, Cioókiewicz A, et al. Coexistence sclerozis, scleroderma-like syndromes and neoplastic diseas: Pol Arch Med wewn. 2008;118:119-26.
Fujimoto M, Hamaguchi Y, Kaji K, et al. Myositis-specific anti155/140 autoantibodies target transcription intermediary factor family proteins.Arthritis Rheum. 2012:64(2):513–522, 2012.
Trallero-Araguás E, Rodrigo-Pendás JÁ, Selva-O’Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523–532.
Andrác C. et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J. Rheumatol. 2008;35,438-444.
Boin F, Hummers LK. Scleroderma-like fibrosing disorders. Rheum Dis Clin North Am 2008; 34:199.
Lakhanpal S, Ginsburg WW, Michet CJ, et al. Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum. 1988; 17:221.
Bischoff L, Derk CT. Eosinophilic fasciitis: demographics, disease pattern and response to treatment: report of 12 cases and review of the literature. Int J Dermatol. 2008; 47:29.
Schwartz RA, Nervi SJ. Erythema nodosum: a sign of systemic disease. Am Fam Physician. 2007;75(5):695-700.
Thomson GT, Keystone EC, Sturgeon JF, et al. Erythema nodosum and non-hodgkin’s lymphoma. J Rheumatol 1990;17:383-5.
Pellkofer HL, Armbruster L, Krumbholz M, et al. Lambert-Eaton myasthenic syndrome differential reactivity of tumor versus non-tumor patients to subunits of the voltage-gated calcium channel. J Neuroimmunol. 2008;204:136-9.
Motomura M, Lang B, Jhonston I, et al. Incidence of serum anti-P/Q type and N-type calcium channel autoantibadies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci. 1997;147:35-42.
Ameratunga R, Daly M, Caughey DE. Metastatic malignancy associated with reflex sympathetic dystrophy. J Rheumatol. 1989;16:406-7.
Chefchaouni MC, Francon C, Thiounn N, Gerbaund PF, et al. Severe algoneurodystrophy of the right foot associated with prostatic cancer. J Urol (paris).1996;102:243-5.
Chong, W.H Molinolo A.A, Chen C.C et al. Tumor-induced osteomalacia. Endocr. Relat. Cancer. 2011;18, R53–R77.
Schumacher HR Jr. Articular manifestations of hypertrophic pulmonary osteoarthropaty in bronchogenic carcinoma. Arthritis Rheum. 1967;19:629-36.
Schapira D, Ben Izhak O, Nachtigal A, et al. Tumor-induced osteomalacia. Semin Arthritis Rheum. 1995;25:35-36.
Cohen PR. Granuloma annulare, relapsing polychondritis, sarcoidosis, and systemic lupus erythematosus: conditions whose dermatologic manifestations may occur as hematologic malignancy-associated mucocutaneous paraneoplastic syndromes. Int J Dermatol. 2006;45(1):70-80.
Yanagi T, Matsumura T, Kamekura R, et al. Relapsing polycondritis and malignat lymhoma: is plycondritis paraneoplastic. Arc Dermatol. 2007;143:89-90.
Valenzuela R, Cooperrider PA, Gogate P. Relapsing polychondritis; immunomicroscopic findings in cartilage ear biopsy specimens. Hum Pathol. 1980;11:19–22.
Buckner JH, Van Landeghen M, Kwok WW, et al. Identification of type II collagen peptide 261-273-specific T cell clones in a patient with relapsing polychrondritis. Arthritis Rheum. 2002;46:238–244.
Damiani JM, Levine HL. Relapsing polychondritis. Report of ten cases. Laryngoscope. 1979;89. p. 929–46.
Shimizu J, Oka H, Yamano Y, Yudoh K, Suzuki N. Cutaneous manifestations of patients with relapsing polychondritis: an association with extracutaneous complications. Clin Rheumatol. 2016;35(3):781-3.
Racanelli V, Prete M, Minoia C, et al. Rheumatic disorders as paraneoplastic syndromes. Autoimmun Rev. 2008;7:352-8.
Szekanecz Z, Szekanecz E, Bakó G, et al. Malignancies in autoimmune rheumatic diseases - a mini review. Gerontology. 2011;57:3-10.
Nunnink JC, Krusinski PA, Yates JW. Multicentric reticulohistiocytosis and cancer: a case report and review of the literature. Med Pediatr Oncol. 1985;13:273-9.
Lambert CM, Nuki G. Multicentric reticulohistiocytosis with arthritis and cardiac infiltration: regression following treatment for underlying malignancy. Ann Rheum Dis.1992;51:815-7.
Johnson J J, Leonard-Segal A & Nashel DJ. Jaccoud's-type arthropathy: an association with malignancy. Journal of Rheumatology. 1989;16: 1278±1280.
Caldwell DS, McCallum RM. Rheumatologic manifestations of cancer. Medical Clinics of North America. 1986;70: 385±417.
Gruber BL, Miller F, Kaufman LD. Simultaneous onset of systemic sclerosis (scleroderma) and lung cancer: a case report and histologic analysis of fibrogenic peptides. American Journal of Medicine. 1992; 92:705±708.
Adel G. Fam. Paraneoplastic rheumatic syndromes. Clinical Rheumatology. 2000;14(3), 515-33.
Szekanecz E, Andras C, Sandor Z, et al. Malignancies and soluble tumor antigens in rheumatic diseases. Autoimmun Rev. 2006;6:42–7.
